Learning From Social Media For Adverse Event Reporting
By Mei Sheng Duh, Brian Ellman, Marc Van Audenrode, Paul Greenberg and Pierre Cremieux (May 23, 2017, 10:29 AM EDT) -- Those interested in monitoring drug safety in the post-marketing setting have been exploring how best to capitalize on the vast amount of information available through social media platforms. While recent studies have suggested that social media may provide a useful source of additional information on patients' experiences after exposure to pharmaceutical and biotechnology products, they also highlight serious limitations on the use and interpretation of such data. As researchers continue to develop tools and methods to analyze social media data, it becomes necessary to consider how best to use those data and, perhaps more importantly, limitations to their uses in identifying and evaluating drug-induced adverse events ("AEs")....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
